6 Results for "

25-carboxylic

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "25-carboxylic" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-12407
CAS No.: 186371-96-0
Purity:  ≥98.0%
Target:  

VD/VDR

Research Areas:  

Metabolic Disease

ZK168281 is a 25-carboxylic ester 1α,25(OH)2D3 analog and a pure VDR antagonist with a Kd value of 0.1 nM. ZK168281 is an effective inhibitor of the coactivator (CoA) interaction of its receptor .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12397
CAS No.: 156965-15-0
Purity:  99.23%
Target:  

VD/VDR

Research Areas:  

Endocrinology

ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character .
loading...
    loading...
Cat. No.: HY-114118S
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-114118S1
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-P10563
CAS No.: 2580150-96-3
Synonyms: BHV-1100
Target:  

CD38 IFNAR

Research Areas:  

Cancer

Noraramtide (BHV-1100) is an antibody-recruiting molecule. Noraramtide binds to CD38 and recruits natural killer (NK) cells to mediate antibody-dependent cellular cytotoxicity. Noraramtide enhances the capacity of autologous cytokine-induced memory-like (CIML) NK cells to produce IFNγ and CD107a, thereby improving their cytotoxicity against multiple myeloma cells. Noraramtide can be used in the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-P11243
Target:  

Ephrin Receptor

Research Areas:  

Neurological Disease

EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
loading...
    loading...